New drug cocktail targets Hard-to-Treat breast cancer spread to brain

NCT ID NCT05800275

Recruiting now Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two oral chemotherapy drugs (tucatinib and capecitabine) plus a targeted antibody given directly into the spinal fluid (trastuzumab) for people with HER2-positive breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases). The goal is to see if this treatment improves survival at 12 months. About 30 adults with this condition will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma Meningeal Carcinomatosis Meningeal Neoplasms neoplastic meningitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE METASTATIC BREAST CANCER LEPTOMENINGEAL DISEASE LEPTOMENINGEAL METASTASIS

Contacts and locations

Locations

Centre Antoine Lacassagne
RECRUITING

Nice, 06189, France
Centre François Baclesse
RECRUITING

Caen, 14000, France
Centre Georges-François Leclerc
RECRUITING

Dijon, 21000, France
Centre Henri Becquerel
RECRUITING

Rouen, 7600, France
Centre Jean Perrin
RECRUITING

Clermont-Ferrand, 63011, France
Centre Léon Bérard
RECRUITING

Lyon, 69008, France
Gustave Roussy
RECRUITING

Villejuif, 94805, France
Institut Bergonié
WITHDRAWN

Bordeaux, 33000, France
Institut Jean Godinot
RECRUITING

Reims, 51100, France
Institut de cancérologie Strasbourg Europe - ICANS
RECRUITING

Strasbourg, 67200, France
Institut régional du Cancer de Montpellier
RECRUITING

Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.